This study aims to describe the burden of Post-Kala-Azar Dermal Leishmaniasis and visceral leishmaniasis relapse in a cohort of patients discharged after successful treatment of primary visceral leishmaniasis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of post-kala-azar-dermal leishmaniasis (PKDL)
Timeframe: 12 months
Incidence of VL relapse
Timeframe: 12 months